Additionally, high PSMD12 expression was associated with a shorter progression-free interval (PFI) in patients with GBMLGG, LGG, UVM, LIHC, KICH, ACC, CESC, and KIRP (Figure 1D). Here, PSMD12 is linked to adrenal cortex carcinoma.